Minretumomab

Minretumomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	TAG-72
Clinical data
Other names	CC49
ATC code	V09IX03 (WHO) (125I radiolabelled);
Identifiers
CAS Number	195189-17-4 ;
ChemSpider	none;
UNII	235435CH6L;
	(what is this?) (verify)

Minretumomab (CC49) is a mouse monoclonal antibody[1] that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.[2][3] Apparently, it never got past Phase I clinical trials for this purpose.[4]

Derivatives

A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric[5] and humanized minretumomab,[6] as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.[7]

Radiopharmaceuticals

Iodine (¹²⁵I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in radioimmunoassays such as CA 72-4.[8]

Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (¹³¹I) and lutetium (¹⁷⁷Lu) minretumomab, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in Phase I and II clinical trials.[5]

gollark: * 0.8%

gollark: It's actually top 0.8 in the world for rudeness!

gollark: You'll note the lack of stuff like "courts" and "law and order".

gollark: If you do that, you are a total bee.

gollark: No.

References

"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (3). 1999.
"TAG-72 antigen". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.
Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872.
"Studies found for: CC49". ClinicalTrials.gov.
Trahan Rieger P, ed. (2001). Biotherapy (2nd ed.). Jones and Bartlett. pp. 334–335. ISBN 0-7637-1428-3.
Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW (February 2010). "Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72". Cancer. 116 (4 Suppl): 1059–66. doi:10.1002/cncr.24793. PMC 4498458. PMID 20127951.
Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, et al. (2006). "Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)". Bioconjugate Chemistry. 17 (2): 410–8. doi:10.1021/bc0503521. PMID 16536473.
Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, et al. (November 1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer Research. 56 (22): 5293–8. PMID 8912871.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (3). 1999.

[2] "TAG-72 antigen". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.

[3] Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872.

[4] "Studies found for: CC49". ClinicalTrials.gov.

[Trahan-5] Trahan Rieger P, ed. (2001). Biotherapy (2nd ed.). Jones and Bartlett. pp. 334–335. ISBN 0-7637-1428-3.

[6] Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW (February 2010). "Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72". Cancer. 116 (4 Suppl): 1059–66. doi:10.1002/cncr.24793. PMC 4498458. PMID 20127951.

[7] Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, et al. (2006). "Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)". Bioconjugate Chemistry. 17 (2): 410–8. doi:10.1021/bc0503521. PMID 16536473.

[8] Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, et al. (November 1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer Research. 56 (22): 5293–8. PMID 8912871.